Tags

Type your tag names separated by a space and hit enter

Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin.

Abstract

AIM

To assess the clinical, biochemical and virological long-term outcome in chronic hepatitis C (CHC) patients with a sustained virological response (SVR) after peginterferon (PEG-IFN) plus ribavirin combination therapy.

METHODS

One hundred and fifty three patients with a SVR after treatment with PEG-IFN plus ribavirin were included in a 5-year follow-up study in a single Spanish center, based on standard clinical practice. Clinical anamnesis, biochemical analysis, hepatitis C virus RNA and alpha-fetoprotein measurement, ultrasonography and transient elastography were performed annually.

RESULTS

The mean follow-up period of the 153 patients was 76 ± 13 mo after they obtained a SVR. Five patients (3.26%) presented with cirrhosis before treatment and 116 (75.8%) had genotype 1. No patient showed evidence of hepatic decompensation. One patient (0.65%) developed a hepatocellular carcinoma at month 30 after achieving SVR. There were no virological relapses during this follow-up period. Persistently elevated alanine aminotransferase was found in only one patient (0.65%). At the end of the 5-year follow-up, the mean value of transient elastography was 7 ± 4.3 kPa (F1). There were no deaths and no other tumors.

CONCLUSION

The long-term outcome of 153 CHC patients with SVR to PEG-IFN plus ribavirin was good. No evidence of a virological relapse was seen. One patient (0.65%) developed a hepatocellular carcinoma.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Gastroenterology-Hepatology Department, University Hospital La Princesa and Princesa Research Institute, Autonomous University of Madrid and CIBERehd, C/Diego de León 62, Madrid, Spain. mtraperomarugan@hotmail.com

    , , , , ,

    Source

    World journal of gastroenterology 17:4 2011 Jan 28 pg 493-8

    MeSH

    Adult
    Antiviral Agents
    Drug Therapy, Combination
    Female
    Fibrosis
    Hepacivirus
    Hepatitis C, Chronic
    Humans
    Interferon alpha-2
    Interferon-alpha
    Male
    Middle Aged
    RNA, Viral
    Recombinant Proteins
    Ribavirin
    Treatment Outcome

    Pub Type(s)

    Journal Article

    Language

    eng

    PubMed ID

    21274379

    Citation

    Trapero-Marugán, María, et al. "Long-term Outcome of Chronic Hepatitis C Patients With Sustained Virological Response to Peginterferon Plus Ribavirin." World Journal of Gastroenterology, vol. 17, no. 4, 2011, pp. 493-8.
    Trapero-Marugán M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol. 2011;17(4):493-8.
    Trapero-Marugán, M., Mendoza, J., Chaparro, M., González-Moreno, L., Moreno-Monteagudo, J. A., Borque, M. J., & Moreno-Otero, R. (2011). Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World Journal of Gastroenterology, 17(4), pp. 493-8. doi:10.3748/wjg.v17.i4.493.
    Trapero-Marugán M, et al. Long-term Outcome of Chronic Hepatitis C Patients With Sustained Virological Response to Peginterferon Plus Ribavirin. World J Gastroenterol. 2011 Jan 28;17(4):493-8. PubMed PMID: 21274379.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. AU - Trapero-Marugán,María, AU - Mendoza,Jorge, AU - Chaparro,María, AU - González-Moreno,Leticia, AU - Moreno-Monteagudo,José Andrés, AU - Borque,María Jesús, AU - Moreno-Otero,Ricardo, PY - 2010/05/22/received PY - 2010/10/07/revised PY - 2010/10/14/accepted PY - 2011/1/29/entrez PY - 2011/1/29/pubmed PY - 2011/7/19/medline KW - Chronic hepatitis C KW - Long-term effects KW - Peginterferon KW - Ribavirin KW - Sustained virological response SP - 493 EP - 8 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 17 IS - 4 N2 - AIM: To assess the clinical, biochemical and virological long-term outcome in chronic hepatitis C (CHC) patients with a sustained virological response (SVR) after peginterferon (PEG-IFN) plus ribavirin combination therapy. METHODS: One hundred and fifty three patients with a SVR after treatment with PEG-IFN plus ribavirin were included in a 5-year follow-up study in a single Spanish center, based on standard clinical practice. Clinical anamnesis, biochemical analysis, hepatitis C virus RNA and alpha-fetoprotein measurement, ultrasonography and transient elastography were performed annually. RESULTS: The mean follow-up period of the 153 patients was 76 ± 13 mo after they obtained a SVR. Five patients (3.26%) presented with cirrhosis before treatment and 116 (75.8%) had genotype 1. No patient showed evidence of hepatic decompensation. One patient (0.65%) developed a hepatocellular carcinoma at month 30 after achieving SVR. There were no virological relapses during this follow-up period. Persistently elevated alanine aminotransferase was found in only one patient (0.65%). At the end of the 5-year follow-up, the mean value of transient elastography was 7 ± 4.3 kPa (F1). There were no deaths and no other tumors. CONCLUSION: The long-term outcome of 153 CHC patients with SVR to PEG-IFN plus ribavirin was good. No evidence of a virological relapse was seen. One patient (0.65%) developed a hepatocellular carcinoma. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/21274379/abstract/ebm/journal/World_journal_of_gastroenterology L2 - http://www.wjgnet.com/1007-9327/full/v17/i4/493.htm DB - PRIME DP - Unbound Medicine ER -